From October 6 to 8, the Infogyn gynecology congress was held, chaired and led by members of several learned societies, including the National College of Obstetrics Gynecology of France (CNGOF).
And this year, a module was dedicated to transgender people, and entitled “Transgender: a current reality”. The opportunity for Dr. Marie D’Assigny, endocrinologist at the University Hospital of Poitiers, to emphasize the importance of reinforced medical monitoring for people in gender transition and on hormone therapy.
After detailing the various hormonal treatments and their usual dosages, the endocrinologist focused on the health risks and the necessary medical supervision. Feminizing hormone therapy would thus increase the risk of thromboembolic diseases, hypertension and cardiovascular diseaseswhile its masculinizing counterpart would notably increase the risk of polyglobulie (abnormal increase in the number of red blood cells in the blood), alopecia, sleep apnea or liver problems.
Citing a study published in October 2021 in the journal The Lancet Diabetes and EndocrinologyDr. Marie D’Assigny indicates that the trans population has a risk of mortality twice as large as the cisgender population, the one whose gender matches the sex assigned at birth. In question, “cardiovascular risk factors and cardiovascular diseases”,…
